Newcomer L N, Cadman E C, Nerenberg M I, Chen M, Bertino J R, Farber L R, Prosnitz L R
Cancer Treat Rep. 1982 Jun;66(6):1279-84.
Two combination chemotherapy programs, ACOMLA (doxorubicin, cyclophosphamide, vincristine, methotrexate and leucovorin rescue, and cytarabine) and CHOP-B (cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin), were evaluated in 29 prospective randomized patients with advanced diffuse histiocytic lymphoma. A complete response was achieved in 13 of the 15 patients (87%) treated with CHOP-B and in nine of the 14 patients (64%) treated with ACOMLA. The overall complete response rate was 75%. Two patients treated with ACOMLA and none of the CHOP-B-treated patients have relapsed. Median followup is 32 months for ACOMLA patients and 26 months for CHOP-B patients. Actuarial freedom from relapse at 2 years is 49.9% for ACOMLA and 93.3% for CHOP-B (P = 0.04). Toxicity was substantial, with eight nonfatal episodes of sepsis and three drug-related deaths. There have been no central nervous system relapses. Although patients treated with CHOP-B have a better response rate, the small numbers of patients treated to date preclude definitive conclusions.
对29例晚期弥漫性组织细胞淋巴瘤患者进行了前瞻性随机分组，评估了两种联合化疗方案，即ACOMLA方案（多柔比星、环磷酰胺、长春新碱、甲氨蝶呤及亚叶酸钙解救，以及阿糖胞苷）和CHOP-B方案（环磷酰胺、多柔比星、长春新碱、泼尼松及博来霉素）。接受CHOP-B方案治疗的15例患者中有13例（87%）获得完全缓解，接受ACOMLA方案治疗的14例患者中有9例（64%）获得完全缓解。总体完全缓解率为75%。接受ACOMLA方案治疗的2例患者复发，接受CHOP-B方案治疗的患者均未复发。ACOMLA组患者的中位随访时间为32个月，CHOP-B组患者为26个月。ACOMLA组2年无复发生存率为49.9%，CHOP-B组为93.3%（P = 0.04）。毒性反应严重，发生8次非致命性脓毒症发作，3例与药物相关死亡。未发生中枢神经系统复发。尽管接受CHOP-B方案治疗的患者缓解率更高，但由于目前治疗的患者数量较少，无法得出明确结论。
